A new pharmaceutical industry association, the European Medicines GroupPharmaceutical-industrydoi:Pharmaceutical-industryPharmacoeconomics & Outcomes News
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulatio...
with Croatia (36%), Spain (34%) and Serbia (31%) having the highest prevalence. It is of importance to note that in all countries included in this study, BZD availability on the pharmaceutical market is bound to medical prescription. Country of residence was in our study recognized...
ECJ 2010/6 Association of the British Pharmaceutical Industry v. Medicines and Healthcare Products Regulatory Agency, 22 April ... A Baeyens,T Goffin - 《European Journal of Health Law》 被引量: 0发表: 2010年 ECJ Gives Public Bodies the Green Light to Induce Doctors to Prescribe Cheaper ...
is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unm...
全部来源 求助全文 europeanpharmaceuticalreview.com 相似文献Bristol-Myers Squibb to present range of new hepatitis C data at the 2013 American Association for the study of liver diseases (AASLD) annual meeting - Eur... B Daniels,BMS Company...
Drug Discovery 2009 - In association with SBS and BPS - European Pharmaceutical ReviewELRIGShow Preview
R v. Secretary of State for Health Ex P. British Association of European Pharmaceutical Distributors and Dowelhurst LTDdoi:10.5235/elr.v5n1.464J Thomas
European Court of Justice. ECJ 2010/6 Association of the British Pharmaceutical Industry v. Medicines and Healthcare Products Regulatory Agency, 22 April 2010 (C-62/09).The judgment has been issued following preliminary rulings and concerns the interpretation of Article 94(1) of Directive 2001/...
Vitamin supplements are over-the-counter medications consumed by the majority of adults. Given that many supplements may be ineffective and/or associated with adverse events, compliance of the registered trials to the European Medicines Agency (EMA) rule